Symbols

MNPR

Monopar Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Consensus Rating "Strong Buy"

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MNPR

Monopar Therapeutics Inc.

A biotech company developing cancer and rare disease treatments in the US

Industry

Biological Technology

Established Date

12/05/2014

Listing Date

12/19/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.monopartx.com

Security Type

Common stock

Office address

1000 Skokie Blvd. Suite 350 Wilmette IL 60091

Business

Introduction

Monopar Therapeutics Inc. was founded on December 5, 2014. The company is a clinical-stage biopharmaceutical company developing innovative treatments for Wilson's disease and novel radiopharmaceuticals in oncology.

Company Financials

EPS

MNPR has released its 2025 Q4 earnings. EPS was reported at -0.61, versus the expected -0.08, missing expectations. The chart below visualizes how MNPR has performed over recent quarters, highlighting trends in earnings surprises.